Gain therapeutics logo
WebApr 5, 2024 · Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. WebApr 10, 2024 · The MarketWatch News Department was not involved in the creation of this content. Apr 10, 2024 (The Expresswire) -- New "Anaplastic Large Cell Lymphoma Therapeutics Market" research report offers ...
Gain therapeutics logo
Did you know?
WebGain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery … WebApr 20, 2024 · Gain will use its proprietary SEE-Tx computational platform technology to identify new sites on target proteins for potential use in oncology. SEE-Tx applies a …
http://grin2b.com/2024/09/29/introducing-grin-therapeutics/ WebAug 3, 2024 · The market expects Gain Therapeutics, Inc. (GANX) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended …
WebMay 10, 2024 · Completed successful initial public offering and raised $46 million in gross proceeds---Appointed four new independent board of directors to stren... WebThe 7 analysts offering price forecasts for Gain Therapeutics have a median target of 15.14, with a high estimate of 30.00 and a low estimate of 4.00. The median estimate represents a 24.10...
WebApr 12, 2024 · BETHESDA, Md., April 12, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced the appointment of C. Evan Ballantyne as the Company’s Chief Financial …
WebJun 10, 2024 · Gain Therapeutics, Inc. is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2024 with the ... mayflower national parks of the southwestWebApr 14, 2024 · CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, … hert medical meaninghertme campingWebLast Funding Type Series B. Legal Name Gain Therapeutics, Inc. Stock Symbol NASDAQ:GANX. Company Type For Profit. Contact Email [email protected]. … mayflower navigatorWebNov 10, 2024 · BETHESDA, Md, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company directly addressing the urgent need for effective... hert meanWebAbout us. Gain Therapeutics is a biotechnology company focused on developing new medicines for protein misfolding diseases. Their supercomputer-driven target-based drug discovery platform, “SEE ... hertme festival 2022WebJan 12, 2024 · Gain Therapeutics, Inc. is transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sites and creating small molecule treatments to address unmet medical needs. The ability to identify never-seen-before allosteric targets on proteins involved in diseases across the full spectrum of ... mayflowernc.org